SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new preclinical
data for etrasimod, an investigational, once-daily, oral, selective
sphingosine 1-phosphate (S1P) receptor modulator, in development
for a range of immune-mediated and inflammatory conditions,
including the expected initiation of a Phase 2 trial in atopic
dermatitis later this year. These data will be presented at
the 49th Annual European Society for Dermatologic
Research (ESDR) Meeting. The meeting is taking place
September 18-21, in Bordeaux, France.
Presentation Details:
Title: Etrasimod, an
Oral, Selective Sphingosine 1-Phosphate Receptor Modulator Improves
Skin Inflammation in a Contact Hypersensitivity Model of
Dermatitis
Poster Number: 30
The e-poster abstract was also selected for presentation as
part of the Inflammation, Immunity and Infection poster
walk.
Poster Walk Details:
Walk Title: Inflammation,
Immunity and Infection 7: Innate immunity and skin Inflammation
Walk Session: Walk 21 (Kiosk 1)
Walk Time: Saturday, September
21, at 10:35-11:35 AM CEST
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology to patients globally. Arena's proprietary pipeline
includes multiple potentially first- or best-in-class assets with
broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune-mediated and inflammatory
conditions, is being evaluated in later-stage clinical programs in
ulcerative colitis (UC) and Crohn's disease (CD), as well as in
programs for other indications such as atopic dermatitis. Arena is
also evaluating olorinab (APD371) in a Phase 2 program for
gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
identified by introductory words such as "will," "in development
for," "expected," "later this year," "driven to," "potentially,"
"potential," "evaluating," or words of similar meaning, or by the
fact that they do not relate strictly to historical or current
facts. Such forward-looking statements include statements about
Arena's participation in the upcoming meeting; the opportunity,
development and potential of etrasimod, including the expected
initiation of a trial in atopic dermatitis; Arena's drive; and the
potential of Arena's assets, programs, licenses, and partnerships.
For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-new-preclinical-atopic-dermatitis-data-for-etrasimod-at-the-european-society-for-dermatologic-research-annual-meeting-300919341.html
SOURCE Arena Pharmaceuticals, Inc.